# AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

> **NCT04499248** · PHASE1,PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 96 (estimated)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** AGN-193408 SR
- **OTHER:** Lumigan
- **OTHER:** Sham Administration
- **OTHER:** Lumigan Vehicle
- **DRUG:** AGN-193408 SR
- **OTHER:** Sham Administration
- **OTHER:** Lumigan Vehicle

## Key facts

- **NCT ID:** NCT04499248
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-16
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04499248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04499248, "AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04499248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*